Efficacy and safety of paliperidone palmitate 3-monthly versus 1-monthly formulation in Asian patients with schizophrenia: Subgroup analysis of a randomized, double-blind, noninferiority study

被引：0
|
作者：
Savitz, A. [1 ]
Gopal, S. [1 ]
Xu, H. [1 ]
Zhuo, J. [2 ]
Yu, L. [2 ]
Nuamah, I. [1 ]
Wu, C. [2 ]
Hough, D. [1 ]
Mathews, M. [1 ]
Feng, Y. [2 ]
机构：
[1] Janssen Res & Dev, Titusville, NJ USA
[2] Janssen Res & Dev, Beijing, Peoples R China
来源：
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY | 2016年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
PM419
引用
收藏
页码：201 / 201
页数：1
相关论文
共 50 条
  • [1] PALIPERIDONE PALMITATE 3-MONTHLY COMPARED WITH 1-MONTHLY FORMULATION IN PATIENTS WITH SCHIZOPHRENIA: GLOBAL AND ASIAN SUBPOPULATION ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, NON-INFERIORITY STUDY
    Savitz, A.
    Gopal, S.
    Feng, Y.
    Xu, H.
    Zhuo, J.
    Yu, L.
    Nuomah, I.
    Ravenstijn, P.
    Wu, C.
    Hough, D.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2016, 50 : 166 - 167
  • [2] Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study
    Savitz, Adam J.
    Xu, Haiyan
    Gopal, Srihari
    Nuamah, Isaac
    Ravenstijn, Paulien
    Hough, David
    Mathews, Maju
    Feng, Yu
    Yu, Lu
    Takahashi, Masayoshi
    Liu, Dennis
    Wang, Gang
    Yoon, Jin-Sang
    Chen, Jiahn-Jyh
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2017, 13 : 2193 - 2207
  • [3] Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post Hoc, Subgroup Analysis
    Mathews, Maju
    Pei, Huiling
    Savitz, Adam
    Nuamah, Isaac
    Hough, David
    Alphs, Larry
    Gopal, Srihari
    CLINICAL DRUG INVESTIGATION, 2018, 38 (08) : 695 - 702
  • [4] Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post Hoc, Subgroup Analysis
    Maju Mathews
    Huiling Pei
    Adam Savitz
    Isaac Nuamah
    David Hough
    Larry Alphs
    Srihari Gopal
    Clinical Drug Investigation, 2018, 38 : 695 - 702
  • [5] Symptomatic Remission and Functional Recovery after Paliperidone Palmitate 3-monthly or 1-monthly treatment in Asian Patients with Exacerbated Schizophrenia
    Savitz, Adam
    Xu, Haiyan
    Gopal, Srihari
    Nuamah, Isaac
    Hough, David
    Mathews, Maju
    Feng, Yu
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2016, 19 : 242 - 243
  • [6] Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study
    Savitz, Adam J.
    Xu, Haiyan
    Gopal, Srihari
    Nuamah, Isaac
    Ravenstijn, Paulien
    Janik, Adam
    Schotte, Alain
    Hough, David
    Fleischhacker, Wolfgang W.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2016, 19 (07):
  • [7] Paliperidone Palmitate 3-Monthly vs. 1-Monthly Injectable in Schizophrenia Patients with or without Prior Exposure to Oral Risperidone or Paliperidone
    Mathews, Maju
    Pei, Huiling
    Savitz, Adam
    Nuamah, Isaac
    Elefant, Erica
    Hough, David
    Alphs, Larry
    Gopal, Srihari
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2016, 19 : 197 - 198
  • [8] Comparison of 3-Monthly versus 1-Monthly Paliperidone Palmitate for Time to Onset and Time to Resolution of Extrapyramidal Symptoms in Patients with Exacerbated Schizophrenia
    Mathews, Maju
    Nuamah, Isaac
    Savitz, Adam
    Hough, David
    Najarian, Dean
    Kim, Edward
    Gopal, Srihari
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2016, 19 : 198 - 198
  • [9] Comparison of 3-Monthly versus 1-Monthly Paliperidone Palmitate for Time to Onset and Time to Resolution of Extrapyramidal Symptoms in Patients with Exacerbated Schizophrenia
    Mathews, Maju
    Nuamah, Isaac
    Savitz, Adam
    Hough, David
    Najarian, Dean
    Kim, Edward
    Gopal, Srihari
    BIOLOGICAL PSYCHIATRY, 2016, 79 (09) : 352S - 353S
  • [10] Impact on carer burden when stable patients with schizophrenia transitioned from 1-monthly to 3-monthly paliperidone palmitate
    Lencer, Rebekka
    Paz Garcia-Portilla, Maria
    Bergmans, Paul
    Gopal, Srihari
    Mathews, Maju
    Wooller, Annette
    Pungor, Katalin
    COMPREHENSIVE PSYCHIATRY, 2021, 107
12345